EF001 其他信息 其他信息 不適用 發行人董事 於本公布日期，本公司董事會成員包括執行董事林向紅女士、歐陽西先生及吳祝花女士；非執行董事拿督斯里謝清海；及獨立非執 行董事陳世達博士、黃寶榮先生及李惟宏先生。 第 2 頁 共 2 頁 v 1.1.1 EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 惠理集團有限公司 | | 股份代號 | 00806 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2025年12月31日止年度之末期股息 | | 公告日期 | 2026年3月17日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股息 | | 財政年末 | 2025年12月31日 | | 宣派股息的報告期末 | 2025年12 ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 佈 的 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 會 就 因 本 公 佈 全 部 或 任 何 部 份 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 VALUE PARTNERS GROUP LIMITED 惠理集團有限公 司 （於開曼群島註冊之有限責任公司） （股份代號：806） 截至二零二五年十二月三十一日止年度 的末期業績公佈 財務摘要 下 列 為 報 告 期 間 的 主 要 財 務 摘 要： | 元） | 萬 | | | | | | | （百 | | 港 | | | | 二零二五年 | 二零二四年 | | 變 動 | % | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | ...

| 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00806 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | HKD | | 0.1 | HKD | | 500,000,000 | | 增加 / 減少 (-) | | | 0 | | | | HKD | | 0 | | 本月底結存 | | | 5,000,000,000 | HKD | | 0.1 | HKD | | 500,000,000 | FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 惠理集團有限公司 (於開曼群島註冊成立之有限責任公司) 呈交日期: 2026年3 ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 佈 的 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 會 就 因 本 公 佈 全 部 或 任 何 部 份 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 VALUE PARTNERS GROUP LIMITED 承董事會命 惠理集團有限公司 公司秘書 殷淑玲 香 港，二 零 二 六 年 三 月 三 日 於 本 公 佈 日 期，本 公 司 董 事 會 成 員 包 括 執 行 董 事 林 向 紅 女 士、歐 陽 西 先 生 及 吳 祝 花 女 士；非 執 行 董 事 拿 督 斯 里 謝 清 海；及 獨 立 非 執 行 董 事 陳 世 達 博 士、黃 寶 榮 先 生 及 李 惟 宏 先 生。 （於開曼群島註冊之有限責任公司） （股份代號：806） 董事會會議召開日期 惠 理 集 團 有 限 公 司（「本 公 司」）董 事 會（「董 事 會」）謹 此 公 佈，將 於二零二六年三 ...

Group 1 - The core viewpoint of the article highlights that Huiri Group (00806.HK) experienced a significant increase in stock price, rising nearly 8% [1] - As of the time of reporting, the stock price was up 7.95%, reaching HKD 2.58 [1] - The trading volume for Huiri Group was reported at HKD 7.0224 million [1]

Core Viewpoint - The company, Hui Li Group, anticipates a significant increase in its consolidated profit attributable to shareholders for the fiscal year 2025, projecting approximately HKD 660 million, a substantial rise from HKD 31 million in 2024 [1][6]. Group 1: Financial Performance - The expected profit growth is attributed to an increase in assets under management, which is projected to rise from USD 5.1 billion as of December 31, 2024, to USD 6.2 billion in 2025 [1][6]. - The performance fee income for 2025 is estimated to be around HKD 370 million, a notable increase from HKD 12 million in the previous year [1][6]. - The company is also expected to achieve a net fair value gain from investments of approximately HKD 460 million in 2025, compared to about HKD 132 million in the previous year [1][6]. Group 2: Investment Strategy - The revenue from investments is primarily derived from the company's long-term holdings, which include initial capital investments, fund investments, joint venture investments, and other investments [1][6]. - All investments are managed in accordance with the company's value investment philosophy [1][6].

Core Viewpoint - The company, 惠理集团, is experiencing significant growth in its projected profits for the fiscal year 2025, with an expected profit of approximately 660 million HKD, a substantial increase from 31 million HKD in 2024 [1] Group 1: Financial Performance - The projected profit for 2025 represents a dramatic increase compared to the previous year, indicating strong financial performance [1] - The company's revenue is expected to rise significantly due to an increase in assets under management, which is projected to grow from 5.1 billion USD as of December 31, 2024, to 6.2 billion USD in 2025 [1] - Performance fees are anticipated to reach around 370 million HKD in 2025, a notable increase from 12 million HKD in the previous year [1] Group 2: Investment Gains - The company is expected to achieve net investment fair value gains of approximately 460 million HKD in 2025, compared to about 132 million HKD in the previous year [1] - These gains are primarily derived from the company's long-term investments, which include initial capital investments, fund investments, joint ventures, and other investments [1] - The investment strategy adheres to the company's value investment philosophy, contributing to the positive performance [1]

Core Viewpoint - 惠理集团预计2025年度的合并利润将大幅增长至约6.60亿港元，相较于2024年度的3100万港元显著提升 [1] Financial Performance - 预计2025年度的收入将大幅增加，资产管理规模从2024年12月31日的51亿美元上升至62亿美元 [1] - 2025年度确认的业绩报酬收入预计为约3.70亿港元，较去年同期的1200万港元显著跃升 [1] - 2025年度的投资公平值收益净额预计为约4.60亿港元，而上一年为约1.32亿港元 [1] Investment Strategy - 收益主要源自集团的长期投资持股，包括初投资本投资、旗下基金投资、合资企业的投资及其他投资，均遵循集团的价值投资理念进行管理 [1]

Market Overview - The Hong Kong stock market opened slightly lower, with the Hang Seng Index down 0.2% at 27,210.56 points, the Hang Seng Tech Index down 0.47% at 5,474.25 points, and the National Enterprises Index down 0.19% at 9,250.27 points [1] - Major tech stocks mostly opened lower, with Alibaba down 1.37%, Tencent down 2.01%, and Meituan down 2.48%, while AI application stocks showed strength, with Zhihui up 8.77% and MINIMAX-WP up 5.65% [1] Company Performance - NetEase reported strong performance, with a net revenue of approximately 112.63 billion yuan, a year-on-year increase of 6.96%, and a net profit of approximately 33.76 billion yuan, up 13.68% [2] - NetEase Cloud Music saw a significant profit increase of 75.4%, with a revenue of 7.76 billion yuan and a profit of 2.75 billion yuan, confirming a turning point in performance [2] Industry Trends - The hard technology and manufacturing sectors showed signs of recovery, with Qiu Tai Technology reporting a 22.8% year-on-year increase in camera module sales and an 18.4% increase in fingerprint recognition module sales, driven by demand in IoT and smart automotive sectors [3] - The renewable energy sector also saw growth, with China Resources Power reporting a 28.4% year-on-year increase in electricity sales, and solar power sales soaring by 72.3% [3] Biopharmaceutical Sector - The biopharmaceutical sector experienced significant positive developments, with Rebio Biotech announcing a global exclusive licensing agreement worth up to 4.4 billion USD, leading to a substantial increase in stock price [4] - Heng Rui Pharmaceutical's product was included in a breakthrough therapy list, with projected global sales exceeding 6.5 billion USD in 2024 [4] Capital Market Activity - Industrial capital is actively engaging in buybacks to stabilize the market, with Geely Automobile repurchasing shares worth approximately 20.30 million HKD and other companies like Kingsoft and Bai Rong Cloud also participating in buybacks [5] - Huili Group is expected to see a profit increase of over 20 times in 2025, indicating a strong performance reversal [5] Institutional Insights - There is a divergence in institutional views regarding market fluctuations, with some suggesting that the recent pullback is a liquidity shock, while others believe that valuation recovery is nearly complete [6] - Specific sectors like AI computing and surgical robots are highlighted for potential growth, with expectations for high performance in 2025 and 2026 [6]

Company News - Q Technology (01478.HK) reported a total sales volume of camera modules of 44.071 million units in January, representing a year-on-year increase of 22.8%. Fingerprint recognition module sales reached 19.741 million units, up 18.4% year-on-year, driven by increased overseas customer demand and a growing market share in the IoT and smart automotive sectors [2] - China Resources Power (00836.HK) achieved a sales volume of 23.78879 million megawatt-hours in January, a year-on-year increase of 28.4%. The sales from wind power plants increased by 7.2%, while solar power plant sales surged by 72.3% year-on-year [2] - NetEase-S (09999.HK) projected net revenue of approximately 112.626 billion yuan for 2025, a year-on-year growth of 6.96%, with net profit expected to be around 33.76 billion yuan, up 13.68% [2] - NetEase Cloud Music (09899.HK) anticipates revenue of about 7.759 billion yuan in 2025, with an expected profit of approximately 2.746 billion yuan, reflecting a significant year-on-year growth of 75.4%. The gross margin is expected to reach 35.7%, an increase from 33.7% in 2024, attributed to business scale growth, enhanced monetization capabilities, prudent cost management, and operational leverage [2] - Huitian Group (00806.HK) expects to achieve a consolidated profit attributable to shareholders of approximately 660 million HKD for the fiscal year 2025, a substantial increase from 31 million HKD in the previous year [2] Biotech Developments - Reborn Bio-B (06938.HK) entered into an exclusive global licensing agreement with Madrigal for several siRNA assets, receiving an upfront payment of 60 million USD, with potential cumulative payments of up to 4.4 billion USD upon achieving certain development, regulatory, and commercialization milestones, in addition to potential royalties on net sales [3] - Fuhong Hanlin (02696.HK) completed the first patient dosing in a Phase 1b/2 clinical study of HLX43 in combination with HLX07 or Hansizhuang® for patients with advanced or metastatic colorectal cancer in China [3] - Heng Rui Medicine (01276.HK) announced that its injection of Rukang Trastuzumab has been included in the list of breakthrough therapies, with global sales of similar products expected to reach approximately 6.557 billion USD in 2024 [3] - Saint Bella (02508.HK) made significant progress in its global strategic expansion plan, aiming to extend its reach to the eastern United States, the UK, France, Thailand, and Australia [3] - China National Biotech Group (08247.HK) signed a strategic cooperation agreement with Xiaoshou Medical to jointly promote the enhancement of quality medical resources and grassroots medical service capabilities [3] Buyback Activities - Geely Automobile (00175.HK) repurchased 1.201 million shares at a cost of 20.3042 million HKD, with repurchase prices ranging from 16.67 to 17.08 HKD [4] - Bairong Cloud-W (06608.HK) repurchased 1.66 million shares for 18.9051 million HKD, with share prices between 11.11 and 11.43 HKD [5] - Kingsoft (03888.HK) repurchased 355,200 shares at a cost of 9.9963 million HKD, with repurchase prices ranging from 27.9 HKD to 28.2 HKD [5]